JPRN-jRCT2031200251已完成3 期
A phase III, randomized, double-blind, placebo-controlled, parallel-group, multi-center study to evaluate the efficacy and safety of M605108 in patients with acne vulgaris
ishiura Tomoyuki0 个研究点目标入组 222 人开始时间: 2020年12月16日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 222
研究概览
简要总结
This study demonstrated that 2.5% M605108 once-daily for 12 weeks was efficacious in the treatment of patients with acne vulgaris. Moreover, the regimen was considered well tolerated because the incidence of adverse events leading to study drug discontinuation was low and the severity of most adverse events was mild.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 12age old 至 <= 49age old（—）
- 性别
- All
入选标准
- •Patients with acne vulgaris
排除标准
- •-Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
- •-Patients with a history of hypersensitivity to investigational drug ingredients
- •-Pregnant or lactating women
研究者
相似试验
已完成
2 期
Effectiveness and Safety of 3 Dosing Regimens of CP-690,550 to Placebo in Subjects With Moderate to Severe Chronic Plaque PsoriasisPsoriasisNCT00678210Pfizer197
已完成
2 期
A Phase 2 Study For Patients With A Physician's Diagnosis Of Rheumatoid ArthritisArthritis, RheumatoidNCT00550446Pfizer386
已完成
2 期
Comparison Of 4 CP-690,550 Doses Vs. Placebo, Each Combined With Methotrexate, For The Treatment Of Rheumatoid Arthritis in JapanArthritis, RheumatoidNCT00603512Pfizer140
已完成
2 期
Randomised, Double- Blind, Cross-over Efficacy and Safety Comparison of Three Different Doses of Tiotropium Administered Once Daily Versus Placebo in Patients With Moderate Persistent Asthma.AsthmaNCT01233284Boehringer Ingelheim149
终止
3 期
Study of Safety, Efficacy and Tolerability of Secukinumab Versus Placebo, in Combination With SoC Therapy, in Patients With Active Lupus NephritisLupus NephritisNCT04181762Novartis Pharmaceuticals275